Mamta Parikh, assistant professor in the Department of Internal Medicine and affiliate of the UC Davis Comprehensive Cancer Center, and Primo Lara, Jr., executive associate dean for Cancer Programs and director of the UC Davis Comprehensive Cancer Center, serve as co-authors on publication of the research on the addition of berzosertib, an enzyme inhibitor, to the chemotherapy drug, gemcitabine, in the treatment of patients with metastatic urothelial cancer.  Link